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本文以课题组前期研究中发现的化合物 HJ-47 和 YSM-14 为先导化合物，
通过生物电子等排体理论、药代动力学等药物分子设计理论，设计合成了两个系




作用，例如是化合物 HZN-12，HZN-14，其 IC50 值分别为 1.70 μM和 1.16 μM。
它们对 HepG2, HeLa 和 U87MG2细胞显示出良好的抑制活性，但对 A549、MG63





及其下游靶基因 p21 的表达促进肿瘤细胞的凋亡产生抗肿瘤增殖活性。 
综上，本文以化合物 HJ-47 和 YSM-14 为先导化合物，经结构优化获得的



















As a kind of major disease, cancer threatens our health, and its treatment has 
been valued by the world. With the deepening of the researches, it is found that cancer 
is complex, its growth and survival are not only dependent on a single receptor or a 
single signal pathway. Single-target drugs can not be efficacious to all signal 
pathways of tumors, but the combination of different drugs may affect the absorption 
and metabolism of drugs, even lead to more serious adverse drug reactions. Therefore, 
there come antitumor drugs named multi-target drugs, which are efficacious to 
various targets of one tumors at the same time against tumors' proliferation. 
Compared with single-target drugs, multi-target drugs have the advantages of more 
comprehensive effects, avoiding drugs' interactions and less adverse drug reactions. 
In this paper, we consider compound HJ-47 and YSM-14 as lead compound, 
which are found from our preliminary study. Then according to some theories of drug 
design such as the theories of bioisosterism and pharmacokinetic, we design and 
synthese two series of novel benzamide derivatives including 
N-(1-(2,6-difluorobenzyl) piperidin-4-yl) benzamide derivatives and 
(S)-N-(1,2,3,4-tetrahydronaphthalen-1-yl) cinnamamide derivatives. All of the 




C-NMR and mass spectrum analysis. It 
is found that some compounds show good bioactivities against HepG2 cells from 
preliminary biology experiments. For example, compounds HZN-12 and HZN-14 
exhibit great bioactivities against HepG2 cells, with an IC50 value of 1.70 μM and 
1.16 μM respectively. But they show poor inhibitory activities against A549 cells, 
MG63 cells and MCF-7 cells. These facts tell that compounds HZN-12 and HZN-14 
have specific selectivity to HepG2 cell lines. Then there comes that compounds 
HZN-12 and HZN-14 induce the expression of HIF-1α, p21 和 Cl-caspase3 to 
promote apoptosis of cancer cells. So it is predicted that compounds HZN-12 and 















cell-cycle arrest.  
In conclusion, in this research, it is considered compound HJ-47 and YSM-14 as 
the lead compounds. After design and syhthesis, we gain compound HZN-12 and 
HZN-14, which provid an important foundation for the design of antitumor drugs. 
This series of compounds is potential for drugs, more deep experiment is in progress. 
 

















HCC Hepatocellular Carcinoma 肝细胞癌 
TACE Transcatheter Arterial Chemoembolization 经肝动脉灌注化疗栓塞术 
SAR Structure activity relationships 构效关系 
RTKs Receptor Tyrosine Kinases 酪氨酸蛋白激酶 
AMPK 
Adenosine Mono-hosphate Activated Protein Kinase 
腺苷酸活化蛋白激酶 
VEGF Vascular Endothelial Growth Factor 血管内皮生长因子 
PDGF Platelet Derived Growth Factor 血小板衍生生长因子 
EGFR Epidermal Growth Factor Receptor 内皮生长因子受体 
FGFR Fibroblast Growth Factor Recptor 成纤维细胞生长因子受体 
IGFR Insulin Growth Factor Receptor 胰岛素样生长因子受体 
HGF Hepatocyte Growth Factor 肝细胞生长因子 
HIF Hypoxia Inducible Factor 缺氧诱导因子 
CSC Cancer Stem Cell 肿瘤干细胞 
Tie Tyrosine Kinase 酪氨酸激酶 
TAD Transactivation Domain 反式激活区 
ODDD Oxygen-Dependent-Degradation Domain 氧依赖性降解结构 
PI3K Phosphatudylinositol 3-Kinase 磷脂酰肌醇-3激酶 
PHD 
Prolyl Hydroxylases Domain-containing 
Protein 
脯氨酸氢化酶 
PGK1 Phosphoglycerate Kinase 1 磷酸甘油酸酯激酶 1 















CDKs Cyclin Dependent kinases 细胞周期素依赖激酶 




HOBT 1- Hydroxybenzotriazole 1-羟基苯并三氮唑 
DMF N,N-Dimethylformamide 氮氮二甲基甲酰胺 
HOAc Acetic Acid 乙酸 
Pd/C Palladium 10% on Carbon 钯碳 
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virus, HBV)和丙肝病毒(hepatitis C virus, HCV)感染、黄曲霉毒素、性激素、酒精、
肝硬化、饮水污染、亚硝胺类物质、非酒精性脂肪肝疾病等等[6]。而在这些发病
危险因素中，HBV 和 HCV占据最主要地位，据统计全球约 80%的肝癌疾病是由










































管生成相关的酪氨酸蛋白激酶(receptor tyrosine kinases, RTKs)信号转导通路、
PI3K/Akt 信号转导通路、Ras/Raf/MEK/MAPK 信号转导通路、Wnt/β-Catenin 信
号转导通路、TGF-β 信号转导通路、Hedgehog(Hh)信号转导通路。除此之外，还
有与肿瘤生长增殖共性关系密切的 Notch 信号转导通路、IKK/NF-κB 信号转导通
路等等。而也有很多的靶点因子如血管内皮生长因子(vascular endothelial growth 





的 α 亚基和 β 亚基组成的异二聚体转录因子[17]。目前已经发现的成员有 HIF-1, 
HIF-2, HIF-3三个，又可以细分为 HIF-1α, HIF-1β, HIF-2α, HIF-3α，其中 HIF-1
和 HIF-2的相关研究最为丰富。虽然关于 HIF 在治疗中对肝癌细胞的生长增殖是
产生促进作用还是抑制作用学者们的看法有所不同，有的学者认为在肿瘤组织周
围的缺氧环境下 HIF 的表达增加有利于肝癌血管的生成和侵袭转移，从而促进






















族成员血管内表皮生长因子受体 VEGFR，血小板源生长因子受体 PDGFR 等，
来阻断肿瘤新生血管的形成，从而间接地抑制肿瘤发展并限制其转移复发[22]。




株中 G1/S-特异性周期蛋白-D1(cyclin D1)的表达水平来抑制肝癌细胞的增殖[24]。 
作为已知的蛋白大家族，蛋白激酶(protein kinases)的主要作用是将 ATP 上的
γ-磷酸基转移到下游底物上特定的氨基酸残基来活化其下游底物。蛋白激酶按照
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